Literature DB >> 26195514

Antimicrobial Activity of Fosfomycin-Tobramycin Combination against Pseudomonas aeruginosa Isolates Assessed by Time-Kill Assays and Mutant Prevention Concentrations.

María Díez-Aguilar1, María Isabel Morosini2, Ana P Tedim3, Irene Rodríguez4, Zerrin Aktaş5, Rafael Cantón6.   

Abstract

The antibacterial activity of fosfomycin-tobramycin combination was studied by time-kill assay in eight Pseudomonas aeruginosa clinical isolates belonging to the fosfomycin wild-type population (MIC = 64 μg/ml) but with different tobramycin susceptibilities (MIC range, 1 to 64 μg/ml). The mutant prevention concentration (MPC) and mutant selection window (MSW) were determined in five of these strains (tobramycin MIC range, 1 to 64 μg/ml) in aerobic and anaerobic conditions simulating environments that are present in biofilm-mediated infections. Fosfomycin-tobramycin was synergistic and bactericidal for the isolates with mutations in the mexZ repressor gene, with a tobramycin MIC of 4 μg/ml. This effect was not observed in strains displaying tobramycin MICs of 1 to 2 μg/ml due to the strong bactericidal effect of tobramycin alone. Fosfomycin presented higher MPC values (range, 2,048 to >2,048 μg/ml) in aerobic and anaerobic conditions than did tobramycin (range, 16 to 256 μg/ml). Interestingly, the association rendered narrow or even null MSWs in the two conditions. However, for isolates with high-level tobramycin resistance that harbored aminoglycoside nucleotidyltransferases, time-kill assays showed no synergy, with wide MSWs in the two environments. glpT gene mutations responsible for fosfomycin resistance in P. aeruginosa were determined in fosfomycin-susceptible wild-type strains and mutant derivatives recovered from MPC studies. All mutant derivatives had changes in the GlpT amino acid sequence, which resulted in a truncated permease responsible for fosfomycin resistance. These results suggest that fosfomycin-tobramycin can be an alternative for infections due to P. aeruginosa since it has demonstrated synergistic and bactericidal activity in susceptible isolates and those with low-level tobramycin resistance. It also prevents the emergence of resistant mutants in either aerobic or anaerobic environments.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26195514      PMCID: PMC4576056          DOI: 10.1128/AAC.00822-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  31 in total

1.  Structure and mechanism of the glycerol-3-phosphate transporter from Escherichia coli.

Authors:  Yafei Huang; M Joanne Lemieux; Jinmei Song; Manfred Auer; Da-Neng Wang
Journal:  Science       Date:  2003-08-01       Impact factor: 47.728

2.  Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients.

Authors:  Eric E Smith; Danielle G Buckley; Zaining Wu; Channakhone Saenphimmachak; Lucas R Hoffman; David A D'Argenio; Samuel I Miller; Bonnie W Ramsey; David P Speert; Samuel M Moskowitz; Jane L Burns; Rajinder Kaul; Maynard V Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-10       Impact factor: 11.205

3.  Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients.

Authors:  Dieter Worlitzsch; Robert Tarran; Martina Ulrich; Ute Schwab; Aynur Cekici; Keith C Meyer; Peter Birrer; Gabriel Bellon; Jürgen Berger; Tilo Weiss; Konrad Botzenhart; James R Yankaskas; Scott Randell; Richard C Boucher; Gerd Döring
Journal:  J Clin Invest       Date:  2002-02       Impact factor: 14.808

Review 4.  Pseudomonas aeruginosa: new insights into pathogenesis and host defenses.

Authors:  Shaan L Gellatly; Robert E W Hancock
Journal:  Pathog Dis       Date:  2013-03-15       Impact factor: 3.166

5.  Eradication of Pseudomonas aeruginosa biofilms on cultured airway cells by a fosfomycin/tobramycin antibiotic combination.

Authors:  Gregory G Anderson; Thomas F Kenney; David L Macleod; Noreen R Henig; George A O'Toole
Journal:  Pathog Dis       Date:  2013-01-10       Impact factor: 3.166

6.  Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen.

Authors:  C K Stover; X Q Pham; A L Erwin; S D Mizoguchi; P Warrener; M J Hickey; F S Brinkman; W O Hufnagle; D J Kowalik; M Lagrou; R L Garber; L Goltry; E Tolentino; S Westbrock-Wadman; Y Yuan; L L Brody; S N Coulter; K R Folger; A Kas; K Larbig; R Lim; K Smith; D Spencer; G K Wong; Z Wu; I T Paulsen; J Reizer; M H Saier; R E Hancock; S Lory; M V Olson
Journal:  Nature       Date:  2000-08-31       Impact factor: 49.962

7.  Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection.

Authors:  Bruce C Trapnell; Susanna A McColley; Dana G Kissner; Mark W Rolfe; Jonathan M Rosen; Matthew McKevitt; Lisa Moorehead; A Bruce Montgomery; David E Geller
Journal:  Am J Respir Crit Care Med       Date:  2011-11-17       Impact factor: 21.405

Review 8.  Pseudomonas aeruginosa hypoxic or anaerobic biofilm infections within cystic fibrosis airways.

Authors:  Daniel J Hassett; Mark D Sutton; Michael J Schurr; Andrew B Herr; Charles C Caldwell; Joseph O Matu
Journal:  Trends Microbiol       Date:  2009-02-21       Impact factor: 17.079

9.  Resistance mechanisms of multiresistant Pseudomonas aeruginosa strains from Germany and correlation with hypermutation.

Authors:  B Henrichfreise; I Wiegand; W Pfister; B Wiedemann
Journal:  Antimicrob Agents Chemother       Date:  2007-09-17       Impact factor: 5.191

10.  Detection and susceptibility testing of hypermutable Pseudomonas aeruginosa strains with the Etest and disk diffusion.

Authors:  Maria D Maciá; Nuria Borrell; José L Pérez; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

View more
  14 in total

1.  Use of Calgary and Microfluidic BioFlux Systems To Test the Activity of Fosfomycin and Tobramycin Alone and in Combination against Cystic Fibrosis Pseudomonas aeruginosa Biofilms.

Authors:  María Díez-Aguilar; María Isabel Morosini; Emin Köksal; Antonio Oliver; Miquel Ekkelenkamp; Rafael Cantón
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

Review 2.  Individualising Therapy to Minimize Bacterial Multidrug Resistance.

Authors:  A J Heffernan; F B Sime; J Lipman; J A Roberts
Journal:  Drugs       Date:  2018-04       Impact factor: 9.546

3.  Evaluation of the Bactericidal Activity of Fosfomycin in Combination with Selected Antimicrobial Comparison Agents Tested against Gram-Negative Bacterial Strains by Using Time-Kill Curves.

Authors:  Robert K Flamm; Paul R Rhomberg; Jill M Lindley; Kim Sweeney; E J Ellis-Grosse; Dee Shortridge
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

4.  Potentiation of Aminoglycoside Activity in Pseudomonas aeruginosa by Targeting the AmgRS Envelope Stress-Responsive Two-Component System.

Authors:  Keith Poole; Christie Gilmour; Maya A Farha; Erin Mullen; Calvin Ho-Fung Lau; Eric D Brown
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

5.  Is a New Standard Needed for Diffusion Methods for In Vitro Susceptibility Testing of Fosfomycin against Pseudomonas aeruginosa?

Authors:  María Díez-Aguilar; Laura Martínez-García; Rafael Cantón; María Isabel Morosini
Journal:  Antimicrob Agents Chemother       Date:  2015-12-07       Impact factor: 5.191

6.  fosI Is a New Integron-Associated Gene Cassette Encoding Reduced Susceptibility to Fosfomycin.

Authors:  Karla de Oliveira Pelegrino; Juliana Coutinho Campos; Suely Carlos Ferreira Sampaio; Karina Lezirovitz; Bruna Mara Seco; Mayne de Oliveira Pereira; Darlan Augusto da Costa Rocha; Thomas Jové; Antonio Carlos Nicodemo; Jorge Luiz Mello Sampaio
Journal:  Antimicrob Agents Chemother       Date:  2015-11-09       Impact factor: 5.191

7.  Synergistic combination of two antimicrobial agents closing each other's mutant selection windows to prevent antimicrobial resistance.

Authors:  Xuejie Xu; Li Xu; Ganjun Yuan; Yimin Wang; Yunqiu Qu; Meijing Zhou
Journal:  Sci Rep       Date:  2018-05-08       Impact factor: 4.379

8.  Oxygen Limitation Enhances the Antimicrobial Activity of Fosfomycin in Pseudomonas aeruginosa Following Overexpression of glpT Which Encodes Glycerol-3-Phosphate/Fosfomycin Symporter.

Authors:  Hidetada Hirakawa; Kumiko Kurabayashi; Koichi Tanimoto; Haruyoshi Tomita
Journal:  Front Microbiol       Date:  2018-08-21       Impact factor: 5.640

Review 9.  Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa: Guidelines by the Spanish Society of Chemotherapy.

Authors:  J Mensa; J Barberán; A Soriano; P Llinares; F Marco; R Cantón; G Bou; J González Del Castillo; E Maseda; J R Azanza; J Pasquau; C García-Vidal; J M Reguera; D Sousa; J Gómez; M Montejo; M Borges; A Torres; F Alvarez-Lerma; M Salavert; R Zaragoza; A Oliver
Journal:  Rev Esp Quimioter       Date:  2018-02-23       Impact factor: 1.553

10.  Understanding Ciprofloxacin Failure in Pseudomonas aeruginosa Biofilm: Persister Cells Survive Matrix Disruption.

Authors:  Anaïs Soares; Valérie Roussel; Martine Pestel-Caron; Magalie Barreau; François Caron; Emeline Bouffartigues; Sylvie Chevalier; Manuel Etienne
Journal:  Front Microbiol       Date:  2019-11-13       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.